Toggle Main Menu Toggle Search

ePrints

Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction)

Lookup NU author(s): Dr Alan Bagnall

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Compared with non-smokers, cigarette smokers with ST-segment elevation myocardial infarctions derive greater benefit from fibrinolytic therapy. However, it is not known whether the optimal treatment strategy after fibrinolysis differs on the basis of smoking status. The Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) randomized patients with ST-segment elevation myocardial infarctions to a routine early invasive (pharmacoinvasive) versus a standard (early transfer only for rescue percutaneous coronary intervention or delayed angiography) strategy after fibrinolysis. The efficacy of these strategies was compared in 1,051 patients on the basis of their smoking status. Treatment heterogeneity was assessed between smokers and non-smokers, and multivariable analysis was performed to evaluate for an interaction between smoking status and treatment strategy after adjusting for baseline Global Registry of Acute Coronary Events (GRACE) risk score. Smokers (n = 448) were younger, had fewer cardiovascular risk factors, and had lower GRACE risk scores. They had a lower rate of the primary composite end point of 30-day mortality, reinfarction, recurrent ischemia, heart failure, or cardiogenic shock and fewer deaths or reinfarctions at 6 months and 1 year. Smoking status was not a significant predictor of either primary or secondary end points in multivariable analysis. Pharmacoinvasive management reduced the primary end point compared with standard therapy in smokers (7.7% vs 13.6%, p = 0.04) and non-smokers (13.1% vs 19.7%, p = 0.03). Smoking status did not modify treatment effect on any measured outcomes (p >0.10 for all). In conclusion, compared with non-smokers, current smokers receiving either standard or early invasive management of ST-segment elevation myocardial infarction after fibrinolysis have more favorable outcomes, which is likely attributable to their better baseline risk profile. The beneficial treatment effect of a pharmacoinvasive strategy is consistent in smokers and non-smokers. (C) 2014 Elsevier Inc. All rights reserved.


Publication metadata

Author(s): Tan NS, Goodman SG, Cantor WJ, Tan MK, Yan RT, Bagnall AJ, Mehta SR, Fitchett D, Strauss BH, Yan AT, for the TRANSFER-AMI Investigators

Publication type: Article

Publication status: Published

Journal: American Journal of Cardiology

Year: 2014

Volume: 114

Issue: 7

Pages: 955-961

Print publication date: 01/10/2014

Online publication date: 16/07/2014

Acceptance date: 13/05/2014

ISSN (print): 0002-9149

ISSN (electronic): 1879-1913

Publisher: Excerpta Medica, Inc.

URL: http://dx.doi.org/10.1016/j.amjcard.2014.05.069

DOI: 10.1016/j.amjcard.2014.05.069


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share